KR20190130621A - Chk1 저해제와 wee1 저해제의 조합물 - Google Patents

Chk1 저해제와 wee1 저해제의 조합물 Download PDF

Info

Publication number
KR20190130621A
KR20190130621A KR1020197031509A KR20197031509A KR20190130621A KR 20190130621 A KR20190130621 A KR 20190130621A KR 1020197031509 A KR1020197031509 A KR 1020197031509A KR 20197031509 A KR20197031509 A KR 20197031509A KR 20190130621 A KR20190130621 A KR 20190130621A
Authority
KR
South Korea
Prior art keywords
cancer
compound
wee1
inhibitor
chk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031509A
Other languages
English (en)
Korean (ko)
Inventor
알렉스 보
케빈 클루처
스콧 피터슨
Original Assignee
시애틀 지네틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시애틀 지네틱스, 인크. filed Critical 시애틀 지네틱스, 인크.
Publication of KR20190130621A publication Critical patent/KR20190130621A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197031509A 2017-03-31 2018-03-30 Chk1 저해제와 wee1 저해제의 조합물 Ceased KR20190130621A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480101P 2017-03-31 2017-03-31
US62/480,101 2017-03-31
PCT/US2018/025464 WO2018183891A1 (en) 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors

Publications (1)

Publication Number Publication Date
KR20190130621A true KR20190130621A (ko) 2019-11-22

Family

ID=62002508

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031509A Ceased KR20190130621A (ko) 2017-03-31 2018-03-30 Chk1 저해제와 wee1 저해제의 조합물

Country Status (11)

Country Link
US (1) US20200108074A1 (enExample)
EP (1) EP3600247A1 (enExample)
JP (1) JP2020512977A (enExample)
KR (1) KR20190130621A (enExample)
CN (1) CN110678169A (enExample)
AU (1) AU2018243667A1 (enExample)
CA (1) CA3058457A1 (enExample)
IL (1) IL269409A (enExample)
MX (1) MX2019011506A (enExample)
SG (1) SG11201908788YA (enExample)
WO (1) WO2018183891A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US12318452B2 (en) 2018-09-27 2025-06-03 Dana-Farber Cancer Institute, Inc. Degraders of WEE1 kinase
KR20210150476A (ko) 2019-04-09 2021-12-10 누베이션 바이오 인크. 헤테로시클릭 화합물 및 그의 용도
US20220387468A1 (en) * 2019-10-25 2022-12-08 Astrazeneca Ab Methods of treating cancer
CN114207437B (zh) * 2020-02-27 2024-05-28 国立大学法人北海道大学 筛选抗癌剂的方法和用于治疗胰腺癌的激酶抑制剂的组合药物
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
CN115778962B (zh) * 2022-11-28 2024-09-17 中国医学科学院肿瘤医院 治疗男性食管癌患者的药物及其相关应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003010444A1 (en) 2001-07-23 2003-02-06 Shock-Proof Solutions Pty Ltd Mechanical shock absorbing apparatus
BRPI0412820A (pt) 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
WO2005072733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Dyarylurea compounds as chk-1 inhibitors
KR20070043996A (ko) 2004-07-02 2007-04-26 이코스 코포레이션 Ｃｈｋ1의 억제에 유용한 화합물
CA2577880A1 (en) 2004-08-19 2006-02-23 Icos Corporation Compounds useful for inhibiting chk1
KR20090031459A (ko) * 2005-03-29 2009-03-25 이코스 코포레이션 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CN101686675A (zh) 2007-03-20 2010-03-31 史密丝克莱恩比彻姆公司 化合物
CA2689429C (en) 2007-06-15 2012-08-21 Banyu Pharmaceutical Co., Ltd. Bicycloaniline derivatives
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
CA2750716A1 (en) 2009-02-25 2010-09-02 Msd K.K. Pyrimidopyrimidoindazole derivative
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
US8716297B2 (en) 2011-07-15 2014-05-06 Abbvie Inc. Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2755482B1 (en) * 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
JP2014530867A (ja) 2011-10-20 2014-11-20 アッヴィ・インコーポレイテッド キナーゼのピリドピリミジノン阻害剤
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
MX2014010176A (es) 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
PL2855448T3 (pl) * 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201316024D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2017216559A1 (en) 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP3600247A1 (en) 2020-02-05
CA3058457A1 (en) 2018-10-04
JP2020512977A (ja) 2020-04-30
SG11201908788YA (en) 2019-10-30
US20200108074A1 (en) 2020-04-09
WO2018183891A1 (en) 2018-10-04
AU2018243667A1 (en) 2019-10-17
IL269409A (en) 2019-11-28
CN110678169A (zh) 2020-01-10
MX2019011506A (es) 2019-11-01

Similar Documents

Publication Publication Date Title
KR20190130621A (ko) Chk1 저해제와 wee1 저해제의 조합물
US20240166668A1 (en) Compounds and uses thereof
Konicek et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases
Adon et al. CDK4/6 inhibitors: a brief overview and prospective research directions
US9629850B2 (en) Combination of MEK inhibitors and selective inhibitors of Aurora A kinase
CN106659765B (zh) 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
KR102064626B1 (ko) Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
KR102271344B1 (ko) 디하이드로피라지노-피라진을 사용한 암의 치료
CN112755193A (zh) 使用卫康醇或其衍生物治疗抗酪氨酸激酶抑制剂的恶性肿瘤的方法
TW201722421A (zh) 雙脫水半乳糖醇或其衍生物和類似物藉由ｄｎａ損傷之誘導和細胞周期之延宕治療非小細胞肺癌、神經膠母細胞瘤及卵巢癌之用途
CA2919731A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
Leonetti et al. Targeted therapy for brain tumours: role of PARP inhibitors
AU2014254058A1 (en) Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
TWI233359B (en) Pharmaceutical composition for treating neoplasm
JP2014513144A (ja) 進行性又は転移性固形悪性腫瘍を含む固形悪性腫瘍の治療方法
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
AU2019244793B2 (en) Anticancer pharmaceutical compositions for combined therapy
US10213436B2 (en) Methods of treating cancer using aurora kinase inhibitors
CN112384528A (zh) 波齐替尼与细胞毒剂和/或其他分子靶向剂的组合物及其用途
US20080214521A1 (en) Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors
TW201815395A (zh) 二去水半乳糖醇或其衍生物或類似物於治療小兒中樞神經系統惡性病之用途
CN118510516A (zh) 用于治疗套细胞淋巴瘤的包含阿贝西利和pi3k和/或mtor抑制剂的药物组合
Tenzer et al. Signal transduction inhibitors as radiosensitizers
EP2344156B1 (en) Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191024

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210330

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230904

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231110

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230904

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I